[
  {
    "ts": "2026-01-14T07:37:10+00:00",
    "headline": "Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs",
    "summary": "The GLP-1 giants are the first to try out this new model, but more companies may follow.",
    "url": "https://www.pharmavoice.com/news/lilly-novo-direct-employer-drug-cost-pbm-consumer/809575/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "4db4d2bb-ad4e-395e-b77e-aa626692ff12",
      "content": {
        "id": "4db4d2bb-ad4e-395e-b77e-aa626692ff12",
        "contentType": "STORY",
        "title": "Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs",
        "description": "",
        "summary": "The GLP-1 giants are the first to try out this new model, but more companies may follow.",
        "pubDate": "2026-01-14T07:37:10Z",
        "displayTime": "2026-01-14T07:37:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/3b2c31d041e3be1658c67634d44630da",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Health insurer Molina Healthcare reported second-quarter results on July 27, 2022.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hnFyQHoVgPhLIfqyHtZ7mA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/3b2c31d041e3be1658c67634d44630da.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U28tfaLGLsJT_IbxwN3OmQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/3b2c31d041e3be1658c67634d44630da.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/lilly-novo-direct-employer-drug-cost-pbm-consumer/809575/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-test-direct-employer-073710828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T13:00:20+00:00",
    "headline": "Nvidia Eyes First Breakout Of 2026. These Clues — And An Innovative Deal With Eli Lilly — Bode Well.",
    "summary": "Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.",
    "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/nvidia-stock-eyes-first-breakout-of-2026-with-eli-lilly-ai-collaboration/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "29d673eb-8756-34b8-b3de-fb7f5eab5629",
      "content": {
        "id": "29d673eb-8756-34b8-b3de-fb7f5eab5629",
        "contentType": "STORY",
        "title": "Nvidia Eyes First Breakout Of 2026. These Clues — And An Innovative Deal With Eli Lilly — Bode Well.",
        "description": "",
        "summary": "Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.",
        "pubDate": "2026-01-14T13:00:20Z",
        "displayTime": "2026-01-14T13:00:20Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/29d673eb-8756-34b8-b3de-fb7f5eab5629/nvidia-eyes-first-breakout-of.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3Qspy2SfrKIYEshxHRa3_A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/duRT6Dnmz77p83MsqEDWsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/nvidia-stock-eyes-first-breakout-of-2026-with-eli-lilly-ai-collaboration/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T14:00:00+00:00",
    "headline": "Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®",
    "summary": "Eli Lilly Canada Inc. (\"Lilly\") announced today that Ontario leads the way as the first province to add Olumiant® for severe alopecia areata to its public drug formulary—the first and only treatment for adult patients with severe alopecia areata available through public coverage.",
    "url": "https://finance.yahoo.com/news/ontario-pioneers-access-treatment-severe-140000180.html",
    "source": "CNW Group",
    "provider": "yfinance",
    "raw": {
      "id": "1e955332-af2e-379c-acce-1aa99ebb1f22",
      "content": {
        "id": "1e955332-af2e-379c-acce-1aa99ebb1f22",
        "contentType": "STORY",
        "title": "Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®",
        "description": "",
        "summary": "Eli Lilly Canada Inc. (\"Lilly\") announced today that Ontario leads the way as the first province to add Olumiant® for severe alopecia areata to its public drug formulary—the first and only treatment for adult patients with severe alopecia areata available through public coverage.",
        "pubDate": "2026-01-14T14:00:00Z",
        "displayTime": "2026-01-14T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/cnwgroup.com/947b60ce205f1931a0aa62c5e816eb95",
          "originalWidth": 375,
          "originalHeight": 204,
          "caption": "Lilly Canada (CNW Group/Eli Lilly Canada Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZmcJfFgf4UXt.L40lreuUw--~B/aD0yMDQ7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/947b60ce205f1931a0aa62c5e816eb95.cf.webp",
              "width": 375,
              "height": 204,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g2WN07FmhnEZMQ9R5QRFHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/947b60ce205f1931a0aa62c5e816eb95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "CNW Group",
          "url": "http://www.newswire.ca/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ontario-pioneers-access-treatment-severe-140000180.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ontario-pioneers-access-treatment-severe-140000180.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T13:52:00+00:00",
    "headline": "Is It Time to Dump Your Shares of Eli Lilly?",
    "summary": "What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?",
    "url": "https://www.fool.com/investing/2026/01/14/is-it-time-to-dump-your-shares-of-eli-lilly/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "235751e7-3a81-300e-a75e-62bf22860961",
      "content": {
        "id": "235751e7-3a81-300e-a75e-62bf22860961",
        "contentType": "STORY",
        "title": "Is It Time to Dump Your Shares of Eli Lilly?",
        "description": "",
        "summary": "What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?",
        "pubDate": "2026-01-14T13:52:00Z",
        "displayTime": "2026-01-14T13:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/80506abbdcafdf6360e2a55d5ea572b9",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "People in business attire leaving the starting line on a track.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lm9DmQt02EysCsC2mpKtkA--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/80506abbdcafdf6360e2a55d5ea572b9.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IOIKHIROappQImz9pswWvQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/80506abbdcafdf6360e2a55d5ea572b9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/14/is-it-time-to-dump-your-shares-of-eli-lilly/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/time-dump-shares-eli-lilly-135200635.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T12:45:00+00:00",
    "headline": "PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock",
    "summary": "Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.",
    "url": "https://finance.yahoo.com/news/pfe-market-cap-falls-more-124500360.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "db723028-55a5-3fcf-9b54-44d62c81b401",
      "content": {
        "id": "db723028-55a5-3fcf-9b54-44d62c81b401",
        "contentType": "STORY",
        "title": "PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock",
        "description": "",
        "summary": "Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.",
        "pubDate": "2026-01-14T12:45:00Z",
        "displayTime": "2026-01-14T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfe-market-cap-falls-more-124500360.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfe-market-cap-falls-more-124500360.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T15:49:26+00:00",
    "headline": "Nvidia Eyes First Breakout Of 2026 — But Resistance Remains",
    "summary": "Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.",
    "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/nvidia-stock-eyes-first-breakout-of-2026-with-eli-lilly-ai-collaboration/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "29d673eb-8756-34b8-b3de-fb7f5eab5629",
      "content": {
        "id": "29d673eb-8756-34b8-b3de-fb7f5eab5629",
        "contentType": "STORY",
        "title": "Nvidia Eyes First Breakout Of 2026 — But Resistance Remains",
        "description": "",
        "summary": "Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.",
        "pubDate": "2026-01-14T15:49:26Z",
        "displayTime": "2026-01-14T15:49:26Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/29d673eb-8756-34b8-b3de-fb7f5eab5629/nvidia-eyes-first-breakout-of.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3Qspy2SfrKIYEshxHRa3_A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/duRT6Dnmz77p83MsqEDWsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/nvidia-stock-eyes-first-breakout-of-2026-with-eli-lilly-ai-collaboration/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T14:50:04+00:00",
    "headline": "Here's Why Eli Lilly (LLY) is a Strong Momentum Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finance.yahoo.com/news/heres-why-eli-lilly-lly-145004555.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "99f2e8da-80d9-3697-9065-bc516c613fe0",
      "content": {
        "id": "99f2e8da-80d9-3697-9065-bc516c613fe0",
        "contentType": "STORY",
        "title": "Here's Why Eli Lilly (LLY) is a Strong Momentum Stock",
        "description": "",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "pubDate": "2026-01-14T14:50:04Z",
        "displayTime": "2026-01-14T14:50:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b",
          "originalWidth": 900,
          "originalHeight": 711,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bjs59nqcRE8iEsudL3mMxA--~B/aD03MTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 900,
              "height": 711,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bro_swiyYm6CQ_YbyBgC9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-eli-lilly-lly-145004555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-eli-lilly-lly-145004555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T16:35:00+00:00",
    "headline": "Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030",
    "summary": "Plenty of growth lies ahead for these top healthcare companies.",
    "url": "https://www.fool.com/investing/2026/01/14/prediction-best-performing-healthcare-stocks-2030/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "ac4bfc15-5902-3c6b-b5c5-5b8534fb948a",
      "content": {
        "id": "ac4bfc15-5902-3c6b-b5c5-5b8534fb948a",
        "contentType": "STORY",
        "title": "Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030",
        "description": "",
        "summary": "Plenty of growth lies ahead for these top healthcare companies.",
        "pubDate": "2026-01-14T16:35:00Z",
        "displayTime": "2026-01-14T16:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/18518efdb4f46e17a04e6d30428a3b1a",
          "originalWidth": 1400,
          "originalHeight": 738,
          "caption": "Researchers smile in a lab setting.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dD5LUHTacSoUwhnWc8RcVA--~B/aD03Mzg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/18518efdb4f46e17a04e6d30428a3b1a.cf.webp",
              "width": 1400,
              "height": 738,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FigC99RHF4ydJBWyEeD81Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/18518efdb4f46e17a04e6d30428a3b1a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/14/prediction-best-performing-healthcare-stocks-2030/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prediction-could-best-performing-healthcare-163500168.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T11:51:00+00:00",
    "headline": "Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill",
    "summary": "Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.”",
    "url": "https://www.biopharmadive.com/news/lilly-obesity-pill-orforglipron-fda-decision-dtc-sales/809598/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "9159c265-4288-3059-acc3-04d9c9066d79",
      "content": {
        "id": "9159c265-4288-3059-acc3-04d9c9066d79",
        "contentType": "STORY",
        "title": "Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill",
        "description": "",
        "summary": "Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.”",
        "pubDate": "2026-01-14T11:51:00Z",
        "displayTime": "2026-01-14T11:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/8ff02a124e40e32c10243f75d8c8a2e1",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "David Ricks, CEO of Eli Lilly, speaks alongside U.S. President Donald Trump, administration officials and fellow pharmaceutical executives on November 06, 2025 in Washington, DC.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1u9Re32Z.69y9d3.q5kNYQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/8ff02a124e40e32c10243f75d8c8a2e1.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8RvWVyCDOXOFlLS56Rdufw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/8ff02a124e40e32c10243f75d8c8a2e1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/lilly-obesity-pill-orforglipron-fda-decision-dtc-sales/809598/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-chasing-novo-expects-second-115100527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T17:16:08+00:00",
    "headline": "The Bull Case For Revvity (RVTY) Could Change Following Upbeat 2025 Guidance And New Lilly AI Alliance",
    "summary": "In recent days, Revvity, Inc. updated its outlook for the fourth quarter and full year 2025, guiding to approximately US$772,000,000 in Q4 revenue and about US$2.86 billion for the year, while indicating adjusted earnings per share should exceed its prior guidance range. A separate announcement revealed that Revvity and Eli Lilly are jointly expanding access to Lilly’s TuneLab AI models through Revvity’s Signals platform, underscoring Revvity’s push to embed advanced AI and federated...",
    "url": "https://finance.yahoo.com/news/bull-case-revvity-rvty-could-171608034.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d0c05496-8544-3c66-9e7d-007b3493f705",
      "content": {
        "id": "d0c05496-8544-3c66-9e7d-007b3493f705",
        "contentType": "STORY",
        "title": "The Bull Case For Revvity (RVTY) Could Change Following Upbeat 2025 Guidance And New Lilly AI Alliance",
        "description": "",
        "summary": "In recent days, Revvity, Inc. updated its outlook for the fourth quarter and full year 2025, guiding to approximately US$772,000,000 in Q4 revenue and about US$2.86 billion for the year, while indicating adjusted earnings per share should exceed its prior guidance range. A separate announcement revealed that Revvity and Eli Lilly are jointly expanding access to Lilly’s TuneLab AI models through Revvity’s Signals platform, underscoring Revvity’s push to embed advanced AI and federated...",
        "pubDate": "2026-01-14T17:16:08Z",
        "displayTime": "2026-01-14T17:16:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dF3MhqhVQlxOrPlZ6576PQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iKEosOYcHiWIA3wbQNTRmQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-revvity-rvty-could-171608034.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-revvity-rvty-could-171608034.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVTY"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T19:12:27+00:00",
    "headline": "Novo Nordisk to Keep Pursuing Deals to Expand Obesity Portfolio, CEO Says",
    "summary": "Novo Nordisk (NVO) will keep looking for deals to expand its obesity portfolio, CEO Mike Doustdar sa",
    "url": "https://finance.yahoo.com/news/novo-nordisk-keep-pursuing-deals-191227573.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "95e84b26-37c2-3669-ba94-d98d9e1b6f93",
      "content": {
        "id": "95e84b26-37c2-3669-ba94-d98d9e1b6f93",
        "contentType": "STORY",
        "title": "Novo Nordisk to Keep Pursuing Deals to Expand Obesity Portfolio, CEO Says",
        "description": "",
        "summary": "Novo Nordisk (NVO) will keep looking for deals to expand its obesity portfolio, CEO Mike Doustdar sa",
        "pubDate": "2026-01-14T19:12:27Z",
        "displayTime": "2026-01-14T19:12:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-keep-pursuing-deals-191227573.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-keep-pursuing-deals-191227573.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AKRO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T18:33:58+00:00",
    "headline": "Why Eli Lilly Stock Gained 39.2% In 2025",
    "summary": "The company is benefiting mightily from its portfolio of weight-loss drugs.",
    "url": "https://www.fool.com/investing/2026/01/14/why-eli-lilly-stock-gained-392-in-2025/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "5b20c748-701a-3778-ab66-eaf970635a8c",
      "content": {
        "id": "5b20c748-701a-3778-ab66-eaf970635a8c",
        "contentType": "STORY",
        "title": "Why Eli Lilly Stock Gained 39.2% In 2025",
        "description": "",
        "summary": "The company is benefiting mightily from its portfolio of weight-loss drugs.",
        "pubDate": "2026-01-14T18:33:58Z",
        "displayTime": "2026-01-14T18:33:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/b9da7b9fb6e842f84b454c334ccf5e0d",
          "originalWidth": 1400,
          "originalHeight": 738,
          "caption": "Doctors working on drug research. ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PkeWckgq1YTP9gzB19B1PA--~B/aD03Mzg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/b9da7b9fb6e842f84b454c334ccf5e0d.cf.webp",
              "width": 1400,
              "height": 738,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xD1qPkcTfIIcRZHGwajDeA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/b9da7b9fb6e842f84b454c334ccf5e0d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/14/why-eli-lilly-stock-gained-392-in-2025/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-stock-gained-183358570.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T20:06:00+00:00",
    "headline": "Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk",
    "summary": "Strive Compounding Pharmacy, one of the nation's most celebrated providers of compounded medications, has filed a federal antitrust lawsuit against pharmaceutical giants Eli Lilly and Novo Nordisk, alleging a coordinated effort to suppress competition and limit patient access to lawful compounded GLP-1 medications.",
    "url": "https://finance.yahoo.com/news/strive-compounding-pharmacy-files-landmark-200600637.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "84728bc1-1768-336a-9f04-176cbea7007a",
      "content": {
        "id": "84728bc1-1768-336a-9f04-176cbea7007a",
        "contentType": "STORY",
        "title": "Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk",
        "description": "",
        "summary": "Strive Compounding Pharmacy, one of the nation's most celebrated providers of compounded medications, has filed a federal antitrust lawsuit against pharmaceutical giants Eli Lilly and Novo Nordisk, alleging a coordinated effort to suppress competition and limit patient access to lawful compounded GLP-1 medications.",
        "pubDate": "2026-01-14T20:06:00Z",
        "displayTime": "2026-01-14T20:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/fdbbca6c519625fc1e338111595f5ee8",
          "originalWidth": 400,
          "originalHeight": 210,
          "caption": "Strive Pharmacy Logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WLCS8aSV1AIPbh_vHLkIxA--~B/aD0yMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/fdbbca6c519625fc1e338111595f5ee8.cf.webp",
              "width": 400,
              "height": 210,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QOxQ1Swy.BbnwLdWeb23aQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/fdbbca6c519625fc1e338111595f5ee8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/strive-compounding-pharmacy-files-landmark-200600637.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/strive-compounding-pharmacy-files-landmark-200600637.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T19:35:00+00:00",
    "headline": "Eli Lilly's Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief",
    "summary": "Retatrutide is an exciting GLP-1 drug that has explosive potential.",
    "url": "https://www.fool.com/investing/2026/01/14/eli-lilly-most-promising-weight-loss-drug-may-come/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "539afc6b-6724-3d82-8fd6-469e2f58b469",
      "content": {
        "id": "539afc6b-6724-3d82-8fd6-469e2f58b469",
        "contentType": "STORY",
        "title": "Eli Lilly's Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief",
        "description": "",
        "summary": "Retatrutide is an exciting GLP-1 drug that has explosive potential.",
        "pubDate": "2026-01-14T19:35:00Z",
        "displayTime": "2026-01-14T19:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/5558a46567b68577cf5a36c41dc073b9",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Doctor talking to a patient while making notes.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y90jU0R6fZYMQ9UbbFgYgQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/5558a46567b68577cf5a36c41dc073b9.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oh.M8nOR_.yrqIZcqHPjZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/5558a46567b68577cf5a36c41dc073b9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/14/eli-lilly-most-promising-weight-loss-drug-may-come/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lillys-most-promising-weight-193500864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T14:59:25+00:00",
    "headline": "JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view",
    "summary": "Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings.",
    "url": "https://www.biopharmadive.com/news/jpm26-biotech-ipos-novo-wegovy-gsk-cell-therapy/809600/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "0babcf28-e31a-3514-806e-903876972f58",
      "content": {
        "id": "0babcf28-e31a-3514-806e-903876972f58",
        "contentType": "STORY",
        "title": "JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view",
        "description": "",
        "summary": "Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings.",
        "pubDate": "2026-01-14T14:59:25Z",
        "displayTime": "2026-01-14T14:59:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "BioPharma Dive, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3g5.ulK0vcCqcdyFlYvVw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DH6ljKWVk5FO27mUzvHUcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/jpm26-biotech-ipos-novo-wegovy-gsk-cell-therapy/809600/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-paying-cash-obesity-drugs-145925960.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JPM"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T14:31:00+00:00",
    "headline": "A Fresh IPO That Long-Term Investors Shouldn’t Ignore",
    "summary": "Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.",
    "url": "https://www.marketbeat.com/originals/a-fresh-ipo-that-long-term-investors-shouldnt-ignore/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "503ed41c-a319-3827-b537-e3f7e5341aec",
      "content": {
        "id": "503ed41c-a319-3827-b537-e3f7e5341aec",
        "contentType": "STORY",
        "title": "A Fresh IPO That Long-Term Investors Shouldn’t Ignore",
        "description": "",
        "summary": "Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.",
        "pubDate": "2026-01-14T14:31:00Z",
        "displayTime": "2026-01-14T14:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/c0984dc973a9bd6b4c8bb29b50fc8c90",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "AKTIS Oncology logo above a laboratory dish with glowing molecular particles, representing cancer research and drug development.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.WNddrHoIVURFUj3fznnnQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/c0984dc973a9bd6b4c8bb29b50fc8c90.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JNk8TVpK_A4sjeZp2DVziw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/c0984dc973a9bd6b4c8bb29b50fc8c90.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/a-fresh-ipo-that-long-term-investors-shouldnt-ignore/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fresh-ipo-long-term-investors-143100335.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MDLN"
            },
            {
              "symbol": "SFD"
            },
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "AKTS"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]